Loteprednol Etabonate

Introduction Overview

Generic Name

loteprednol etabonate

Brand Name

Eysuvis

Dosage Form

eye (suspension) drops

Drug Class

Ophthalmic steroids

Pharmacokinetics

Absorption:
Loteprednol etabonate ophthalmic suspension is rapidly absorbed through the corneal and conjunctival tissues upon ocular administration. The drug delivery technology used in Eysuvis, known as Ampplify, enhances penetration through the ocular mucus barrier, increasing drug bioavailability at the target tissues of the eye's surface. This technology allows greater amounts of loteprednol to reach affected tissues in the conjunctiva and cornea, facilitating quicker anti-inflammatory effects. Peak aqueous humor concentrations of the active drug occur within 30 minutes post-administration. The rate and extent of absorption may be influenced by ocular surface integrity, presence of inflammation, and tear film dynamics.

Distribution:
Once absorbed, loteprednol etabonate exhibits high local concentrations in the ocular tissues, including the cornea, conjunctiva, and anterior chamber. Due to its topical dosing and minimal systemic absorption, distribution beyond ocular tissues is very limited, reducing systemic exposure and associated side effects. The drug’s lipophilicity allows for effective penetration into lipid-rich ocular membranes. Minimal systemic plasma levels are detected, indicating limited systemic distribution. The suspension formulation aids in sustained ocular surface residence time and localized activity.

Metabolism:
Loteprednol etabonate is designed as a "soft steroid," undergoing rapid metabolism in ocular tissues to inactive metabolites via ester hydrolysis. This transformation primarily occurs in the corneal and conjunctival tissues, converting loteprednol etabonate to a carboxylic acid metabolite with negligible pharmacological activity. This metabolism reduces systemic corticosteroid exposure and associated risks. The ocular metabolism pathway allows for potent localized effects while limiting systemic side effects often observed with traditional corticosteroids.

Elimination:
Elimination of loteprednol etabonate occurs predominantly through local metabolism in the eye tissues, with inactive metabolites cleared via aqueous humor outflow pathways and tear drainage into the nasolacrimal duct. Systemic elimination pathways are minimal given low systemic absorption but primarily involve hepatic metabolism and renal excretion of inactive metabolites if absorbed. The short ocular residence time coupled with metabolic inactivation allows for a reduced risk of adverse side effects such as increased intraocular pressure or cataract formation with short-term use.

Dosage Forms

Available Dosage Forms:
Eysuvis is available as an ophthalmic suspension eye drop formulated with loteprednol etabonate at a concentration of 0.25%. The suspension incorporates Ampplify drug delivery technology to enhance mucosal penetration.

Dosages for Adults and Adolescents:
The recommended dosage is 1 to 2 drops into each affected eye up to four times daily for short-term use generally not exceeding two weeks. The dosing is intended for the symptomatic relief of dry eye disease flare-ups.

Specific Patient Populations:
Eysuvis is indicated primarily for adults with dry eye disease experiencing acute flare-ups. The safety and efficacy in pediatric populations have not been established. Use in pregnant or breastfeeding women is advised only if the potential benefit justifies potential risk to the fetus or infant. Patients with ocular infections or inflammatory eye conditions requiring steroids should be carefully evaluated before use. Contact lens wearers must remove lenses before application and may reinsert lenses 15 minutes post-instillation owing to preservative absorption in lenses.

Formulation Details:
- Ophthalmic suspension containing loteprednol etabonate 0.25% (2.5 mg/mL)
- Contains excipients such as glycerin, sodium citrate dihydrate, sodium chloride, Poloxamer 407, edetate disodium dihydrate, citric acid, water for injection
- Includes the preservative benzalkonium chloride
- Supplied in a multi-dose bottle with white tamper-evident overcap and a pink dosage cap
- Storage temperature recommendations: store upright at 15°C to 25°C (59°F to 77°F), do not freeze
- Discard if tamper seal is broken or after the expiration date specified on the bottle

Mechanism Of Action

Loteprednol etabonate, the active component of Eysuvis, is a corticosteroid specifically formulated for ophthalmic use with a soft steroid design providing anti-inflammatory effects while minimizing systemic exposure. At the molecular level, loteprednol etabonate binds to glucocorticoid receptors in the cytoplasm of ocular surface cells including epithelial and immune cells, inducing conformational changes that promote receptor translocation into the nucleus.

Upon receptor activation, it modulates the transcription of anti-inflammatory proteins and suppresses the expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. This leads to inhibition of inflammatory cell migration and activation, reduction in the synthesis of prostaglandins and leukotrienes via cyclooxygenase and lipoxygenase pathways, and repression of arachidonic acid release from membrane phospholipids.

At the cellular level, the suppression of inflammatory mediators decreases vascular permeability, tissue edema, and hypersensitivity reactions which are central to the pathogenesis of dry eye disease flare-ups. The mucus-penetrating formulation (Ampplify technology) ensures enhanced drug delivery through the eye's tear film and mucous barriers, allowing effective concentrations to reach corneal and conjunctival epithelial cells, which are the primary sites of inflammation in dry eye.

Clinically, this mechanism translates to rapid symptom relief of redness, burning, irritation, and epithelial disruption seen in dry eye episodes. Compared to traditional corticosteroids, loteprednol’s retrometabolic design allows for quicker metabolic inactivation in the eye, reducing risks of elevated intraocular pressure and cataract formation. Its efficacy and safety profile have been validated in multiple randomized controlled clinical trials demonstrating significant improvement in dry eye symptoms with short-term use while maintaining a low incidence of steroid-related adverse effects.

Pharmacological Actions

Anti-inflammatory effects via glucocorticoid receptor activation
Suppression of pro-inflammatory cytokines and mediators in ocular tissues
Inhibition of leukocyte migration and adhesion in the conjunctiva and cornea
Reduction of vascular permeability and associated tissue edema
Blockade of prostaglandin and leukotriene synthesis pathways
Rapid onset of symptomatic relief in ocular surface inflammation
Soft steroid design allows for localized activity with reduced systemic exposure
Use of Ampplify technology improves drug penetration through ocular mucus barriers
Minimizes steroid-related adverse effects such as intraocular pressure elevation
Improves tear film stability indirectly by reducing ocular surface inflammation
Therapeutic effect limited to short-term treatment due to risks of long-term steroid use
Anti-inflammatory action beneficial in treatment of dry eye disease flare-ups
Metabolized locally in ocular tissues to inactive metabolites limiting systemic toxicity
Preservative inclusion (benzalkonium chloride) enhances antimicrobial protection but requires caution in contact lens wearers

Therapeutic Or Clinical Uses

Short-term treatment of signs and symptoms of dry eye disease flare-ups
Management of ocular surface inflammation associated with dry eye
Reduction of redness, burning, itching, and irritation in dry eye patients
Temporary relief of ocular discomfort caused by decreased tear quality or quantity
Adjunctive therapy for dry eye patients experiencing acute inflammatory episodes
Use in adults for symptomatic relief of dry eye disease up to two weeks
Treatment of non-infectious ocular inflammatory conditions requiring corticosteroid therapy (off-label)
Facilitation of ocular surface healing in inflammatory dry eye states (short-term)
Alternative corticosteroid option with improved safety profile for ocular inflammation
Option when non-steroidal anti-inflammatory drugs are insufficient in dry eye flare-ups
Treatment that can be combined with artificial tears or other supportive dry eye therapies
Use guided by ophthalmic examination and monitoring due to potential adverse effects
Suitable for patients intolerant to other dry eye therapies requiring steroid intervention
Reduces the need for systemic corticosteroid use by providing targeted ocular therapy
Beneficial in controlling inflammatory components of dry eye syndrome refractory to other treatments

Side Or Adverse Effects

Instillation site pain reported in approximately 5% of patients with two weeks’ use
Increase in intraocular pressure (IOP) leading to risk of glaucoma with prolonged use
Formation of posterior subcapsular cataracts after extended corticosteroid exposure
Delayed corneal and conjunctival epithelial healing and surface damage
Potential exacerbation or prolongation of viral eye infections, including herpes simplex
Possible suppression of local immune response increasing risk of secondary bacterial infections
Increased risk of fungal keratitis with long-term corticosteroid use
Ocular irritation, burning, stinging, or redness immediately following instillation
Transient blurred vision upon drop application
Hypersensitivity or allergic reactions to active or inactive ingredients including preservatives
Risk of masking ocular infection signs complicating diagnosis
Potential for contact lens-related complications if lenses not removed prior to use
Risk of contamination if dropper tip contacts surfaces leading to infection
Eyelid edema and conjunctival hyperemia rarely reported
Headache or systemic corticosteroid side effects are exceedingly rare due to minimal systemic absorption

Precautions

Use only as prescribed and for short-term treatment (up to two weeks) to limit risks
Monitor intraocular pressure regularly during therapy to detect steroid-induced glaucoma
Avoid use in patients with known hypersensitivity to loteprednol or formulation components
Discontinue and consult a physician if eye pain, redness, itching, or irritation worsens
Use caution in patients with history or presence of ocular viral infections including herpes simplex keratitis
Avoid use in fungal or mycobacterial eye infections due to risk of exacerbation
Remove contact lenses before application and wait 15 minutes before reinsertion
Avoid contamination by not touching the dropper tip to any surface
Evaluate ocular surface health before and during treatment to detect delayed healing
Do not use in presence of corneal ulcers or active ocular infections without medical advice
Avoid prolonged use to minimize risk of cataract formation and increased IOP
Inform healthcare provider of all concurrent medications and ocular conditions
Exercise caution in patients with glaucoma or ocular hypertension
Discuss pregnancy or breastfeeding plans with healthcare provider prior to use
Educate patient on proper administration technique and storage conditions

Warnings

Risk of increased intraocular pressure leading to glaucoma with prolonged corticosteroid use
Potential development of posterior subcapsular cataracts following long-term therapy
Possible delayed healing and ocular surface damage during treatment
Use may worsen or prolong viral infections of the eye including herpes simplex keratitis
corticosteroids may enhance bacterial, fungal, or mycobacterial ocular infections
Should not be used in corneal viral, fungal, or mycobacterial infections
Use with caution in patients with pre-existing glaucoma or ocular hypertension
Contact lenses must be removed prior to administration to avoid preservative absorption
Avoid contamination of the dropper tip to prevent serious ocular infections
Discontinue therapy if eye pain or discomfort develops to exclude infection
Safety and effectiveness not established for long-term use beyond two weeks
Patients should be advised not to self-medicate or extend use without medical review
Pregnancy and lactation use only if potential benefits justify potential risks
Keep medication out of reach of children to prevent accidental exposure
Do not use if tamper-evident overcap is missing or damaged

Contraindication

Known hypersensitivity to loteprednol etabonate or any component of the formulation
Active viral infections involving the cornea and conjunctiva including epithelial herpes simplex keratitis
Vaccinia or varicella infections of the eye
Mycobacterial infections of the eye
Fungal infections affecting ocular structures
Presence of untreated bacterial ocular infections (relative contraindication)
Use in pediatric patients not established and generally contraindicated without physician supervision
Known hypersensitivity to benzalkonium chloride preservative
Patients with ocular herpes simplex with epithelial keratitis
Corneal ulcers or severe ocular surface damage precluding corticosteroid use
Patients who cannot adhere to dosing instructions or follow monitoring requirements
Pregnancy unless clearly indicated and benefits outweigh risks
Use in presence of ocular hypertension or glaucoma without close monitoring
Concurrent use with other ophthalmic steroids without appropriate medical supervision
Severe ocular surface diseases where steroid risks outweigh benefits

Drug Interactions

Concurrent use with other ophthalmic corticosteroids may increase risk of adverse effects
Potential interaction with ocular hypotensive agents used to treat glaucoma
Use with other preserved eye drops can increase risk of ocular surface irritation
Nonsteroidal anti-inflammatory drugs may have additive or synergistic ocular effects
Systemic corticosteroids do not significantly interact due to minimal systemic absorption
Use with drugs that impair immune response may increase susceptibility to ocular infections
No significant interactions reported with common systemic medications due to topical route
Benzalkonium chloride preservative may interact adversely with soft contact lenses
Concurrent use with cyclosporine ophthalmic drops requires monitoring for additive immunosuppression
Interactions with investigational or novel dry eye medications not fully established
Potential reduction in efficacy if eye drops washed out by excessive tearing or lacrimation
Drug interaction checker should be used to assess polypharmacy in patients on multiple ocular agents
Certain herbal supplements with anti-inflammatory properties may theoretically alter ocular responses
Use caution combining with agents that may increase intraocular pressure
No significant effect on metabolism enzymes due to localized ocular application

Preparations Of The Drug

Eysuvis contains loteprednol etabonate 0.25% ophthalmic suspension
Formulated with Ampplify drug delivery technology to enhance mucosal penetration
Bottle includes white tamper-evident overcap and pink dosing cap
Preserved with benzalkonium chloride to prevent microbial contamination
Excipients include glycerin, sodium citrate dihydrate, sodium chloride, Poloxamer 407, edetate disodium dihydrate, citric acid, water for injection
Supplied in multi-dose 2.5 mL bottles intended for up to two weeks of use
Suspension requires shaking before each use to ensure uniform drug dispersion
Storage recommended between 15°C to 25°C, do not freeze
Discard bottle after expiration or if tamper-evident seal is compromised
Manufactured by Kala Pharmaceuticals, Inc., Watertown, MA
Dosing instructions: instill 1-2 drops in each affected eye up to four times daily
Pre-administration hygiene instructions include hand washing and removal of contact lenses
Not formulated as preservative-free; caution advised for sensitive eyes or contact lens wearers
Packaging includes patient information leaflet and detailed administration guidance
Stable for duration of labeled expiration when stored properly